Joseph Haas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joseph Haas
Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
Ligand Buys Into Ongoing Partnerships With Icagen Deal
Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.
89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile
89Bio thinks its Phase II FGF21 analog could prove best-in-class in NASH due to a longer half-life than Bristol’s pegbelfermin, and avoid the LDL-increasing effects seen with NGM’s FGF19 analog.
Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings
Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.
Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out
Gilead takes $800m impairment charge against Kite acquisition a year after an $820m write-down. Kite and Yescarta are appear to be afterthoughts in discussions of Gilead’s portfolio and pipeline.